| Literature DB >> 27218259 |
Kledoaldo Lima1, Élcio de Souza Leal2, Ana Maria Salustiano Cavalcanti3, Daniela Medeiros Salustiano3, Luzidalva Barbosa de Medeiros4, Sirleide Pereira da Silva3, Heloísa Ramos Lacerda1.
Abstract
BACKGROUND: HIV-1 diversity causes important differences in the virus' biological properties and their interactions with hosts, such as cell tropism, responses to antiretroviral therapy, drug-resistance, and disease progression.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27218259 PMCID: PMC4878750 DOI: 10.1371/journal.pone.0155854
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and laboratory characteristic among HIV-1 subtypes B and non-B.
| Variables | Subtipe B (n = 103) | Subtipe Non-B | Univariate analysis | |
|---|---|---|---|---|
| OR (CI—95%) | p-value | |||
| Male | 66 (64.7%) | 31 (47.7%) | 1.0 | - |
| Female | 36 (35.3%) | 34 (52.3%) | 2.01 (1.02–3.99) | 0.029 |
| 34.0 ± 10.6 | 34.6 ± 10.4 | 0.995 (0.966–1.025) | 0.762 | |
| < 8 years | 50 (56.2%) | 40 (74.1%) | 1.0 | |
| ≥ 8 years | 39 (43.8%) | 14 (25.9%) | 0.45 (0.21–0.93) | 0.033 |
| Single | 24 (47.1%) | 9 (56.3%) | 1.0 | - |
| Married | 19 (37.3%) | 6 (37.5%) | 0.85 (0.28–2.60) | 0.773 |
| Divorced | 3 (5.9%) | 0 | Not calculed | - |
| Windowed | 5 (9.8%) | 1 (6.2%) | Not calculed | - |
| Yes | 4 (10.8%) | 5 (14.7%) | 1.0 | - |
| No | 33 (89.2%) | 29 (85.3%) | 1.42 (0.35–5.80) | 0.623 |
| HTS | 68 (66.7%) | 52 (80%) | 1.0 | - |
| MSM | 34 (33.3%) | 13 (20%) | 0.5 (0.22–1.10) | 0.062 |
| Recent | 12 (22.2%) | 9 (19.1%) | 1.0 | - |
| Long-term | 42 (77.8%) | 38 (80.9%) | 0.83 (0.31–2.18) | 0.704 |
| 226.5 (78; 414) | 341 (159; 488) | - | 0.036 | |
| < 200 cells/mm3 | 32 (39.0%) | 13 (26.5%) | 1.0 | - |
| ≥ 200 cells/mm3 | 50 (61.0%) | 36 (73.5%) | 1.77 (0.77–4.14) | 0.145 |
| 65.000 (7.618; 194.000) | 18.185 (1.470; 53.973) | - | 0.023 | |
| < 100.000 copies/ml | 52 (60.5%) | 40 (76.9%) | 1.0 | - |
| ≥ 100.000 copies/ml | 34 (39.5%) | 12 (23.1%) | 0.46 (0.20–1.06) | 0.047 |
| Negative | 35 (67.3%) | 34 (77.3%) | 1.0 | - |
| Positive | 17 (32.7%) | 10 (22.7%) | 1.65 (0.61–4.55) | 0.279 |
| Negative | 52 (100%) | 43 (97.7%) | 1.0 | - |
| Positive | 1 (2.3%) | Not calculated | - | |
| Negative | 47 (100%) | 44 (100%) | 1.0 | - |
| Positive | Not calculated | - | ||
| Negative | 44 (86.3%) | 37 (84.1%) | 1.0 | - |
| Positive | 7 (13.7) | 7 (15.9) | 0.84 (0.27–2.62) | 0.765 |
HTS, Heterosexuais; MSM, Mens who have sex with men.
Among the 65 HIV-1 subtypes non-B, 53 were subtipe F;
†Statistically significant association;
* Fischer’s exact test;
Median (P25; P75)–Kruskal-Wallis test;
(-) Not detected.
Fig 1Phylogenetic analysis of sequences from 2007–2009.
Bootstrap support values of ≥ 70 were considered significant and only bootstrap of 70 or higher are shown. red circles: co-infections HIV/HBV; Green circles = co-infections HIV/Syphilis; blue circles = co-infections HIV/HBV/Syphilis.
Stratified analysis of individuals with co-infecttion HBV/HIV-1 subtypes B and non-B.
| HIV-1 subtipe B | HIV-1 subtipe non-B | Stratified Statistical Analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Variables | HBV+ n (%) | HBV- n (%) | p-value | HBV+ n (%) | HBV- n (%) | p-value | ORcrude | ORMH |
| (n = 27) | (n = 70) | (n = 27) | (n = 70) | |||||
| MSM | 10 (58.9) | 08 (23.5) | 01 (10) | 06 (17.6) | 0.56 | 2.65(1.00–7.01) | 2.46(0.91–6.61) | |
| HTS | 07 (41.1) | 26 (76.5) | 09 (90) | 28 (82.4) | ||||
| CD4 < 200 | 02 (20) | 06 (22.2) | 0.88 | 01 (14.3) | 12 (23.1) | 0.60 | 0.72(0.18–2.81) | 0.72(0.18–2.87) |
| CD4 ≥ 200 | 08 (80) | 21 (77.8) | 06 (85.7) | 40 (76.9) | ||||
| < 100.000 | 06 (50) | 24 (85.7) | 06 (85.7) | 22 (84.6) | 0.94 | 0.29(0.09–0.98) | 0.31(0.09–1.03) | |
| ≥ 100.000 | 06 (50) | 04 14.3) | 01 (14.3) | 04 (15.4) | ||||
| Male | 15 (88.2) | 20 (57.2) | 03 (30) | 17 (50) | 0.27 | 1.73(0.68–4.08) | 1.58(0.61–4.07) | |
| Female | 02 (11.8) | 15 (42.8) | 07 (70) | 17 (50) | ||||
| < 8 years | 04 (33.3) | 20 (69) | 04 (57.2) | 19 (67.8) | 0.59 | 0.34(0.12–0.98) | 0.34(0.12–1.00) | |
| ≥ 8 years | 08 (66.4) | 09 (31) | 03 (42.8) | 09 (32.2) | ||||
MSM, Men who have sex with men; HTS, Heterosexuais.
¶ Total of samples tested serologically for co-infection HBV-HIV;
§ Available data for each variable in the analysis;
* Fisher's exact test;
χ MSM: Men who have sex with men;
¥ HTS: Heterosexuais;
μ Viral load (copies/ml);
ωOdds ratio Mantel-Haenszel;
Stratified analysis of individuals with co-infecttion Syphilis/HIV-1 subtypes B and non-B.
| HIV-1 subtipe B | HIV-1 subtipe non-B | Stratified Statistical Analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Syphilis+ n (%) | Syphilis- n (%) | p-value | Syphilis+ n (%) | Syphilis- n (%) | p-value | ORcrude | ORMH |
| (n = 14) | (n = 81) | (n = 14) | (n = 81) | |||||
| MSM | 02 (28.6) | 15 (34.9) | 0.77 | 04 (57.1) | 03 (8.8) | |||
| HTS | 05 (71.4) | 28 (65.1) | 03 (42.9) | 31 (91.2) | ||||
| CD4 < 200 | - | 07 (23.3) | 0.23 | 03 (75) | 04 (14.3) | |||
| CD4 ≥ 200 | 05 (100) | 23 (76.7) | 01 (25) | 24 (85.7) | ||||
| < 100.000 | 06 (100) | 24 (75) | 0.17 | 04 (100) | 25 (83.3) | 0.38 | 6.53(0.80–53.51) | 6.57(0.72–59.67) |
| ≥ 100.000 | - | 08 (25) | - | 05 (16.7) | ||||
| Male | 03 (42.9) | 30 (69.8) | 0.17 | 06 (85.7) | 14 (37.8) | |||
| Female | 04 (57.1) | 13 (30.2) | 01 (14.3) | 23 (62.2) | ||||
| < 8 years | 02 (33.3) | 22 (66.7) | 0.14 | 03 (75) | 20 (64.5) | 0.68 | 0.52(0.14–2.00) | 0.54(0.14–2.03) |
| ≥ 8 years | 04 (66.7) | 11 (33.3) | 01 (25) | 11 (35.5) | ||||
MSM, Men who have sex with men; HTS, Heterosexuais.
¶ Total of samples tested serologically for co-infection HBV-HIV;
§ Available data for each variable in the analysis;
* Fisher's exact test;
χ MSM: Men who have sex with men;
¥ HTS: Heterosexuais;
μ Viral load (copies/ml);
ωOdds ratio Mantel-Haenszel;
Drug resistance mutations and antiretroviral resistance profile at patients from Pernambuco, Northeast–Brazil.
| Sequence/ Subtype | Gender/Exposure category/ | PI major mutations | PI minor mutations | ITRN mutations | ITRNN mutations | Drug-resistance profile | ||
|---|---|---|---|---|---|---|---|---|
| Low | Intermediate | High | ||||||
| 08PE165 B | F/HTS/PHIV+/ Syphilis | - | L10V | - | P225H | NFV NVP | EFV | - |
| 08PE121 B | M/HTS/ HBsAg+ | L82A L90M | L10F | - | - | TPV/r | FVP/r LPV/r | ATV/r IDV/r NFV SQV/r |
| 08PE082 B | M/HTS | - | - | V75L F77L M184V | K101E G190S | ABC DDI ETR | RPV | 3TC FTC EFV NVP |
| 09PE172 F | M/MSM | - | L10V | - | K103N | - | - | EFV. NVP |
| 08PE055 BF | M/HTS | - | - | - | G190A | ETR RPV | EFV | NVP |
PI, Protease inhibitors; NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; ABC, abacavir; ATV, atazanavir; DDI, didanosine; EFV, efavirenz; ETR, etravirine; FVP, fosamprenavir; FTC, emtricitabine; IDV, indinavir; PVL, lopinavir; NFV, nelfinavir; NVP, nevirapine; RPV, rilpivirine; SQV, saquinavir; 3TC, lamivudine; HTS, heterosexual; MSM, men who have sex with men; PHIV +, HIV + partner.
¶ Mutations not contained in the SDRM list established by the World Health Organization (WHO) (BENETT et al. 2009). However, according to the HIVdb Program—Stanford University for the evaluation of antiretroviral susceptibility, they may be associated with decreased susceptibility that when combined with other mutations or due to other intrinsic characteristics to each corresponding codon.